单周与3周紫杉醇联合卡铂方案治疗卵巢癌临床疗效分析

Clinical curative effect analysis of the chemotherapy of paclitaxel plus carboplatin weekly and every three weeks in the treatment of ovarian cancer

目的比较单周和3周紫杉醇联合卡铂(TP方案)疗法治疗卵巢癌的安全性、毒副反应、治疗效果和复发时间。方法按照2005年最新临床病理分级分期标准,将46例卵巢癌患者按照随机原则平均分为紫杉醇每周给药组和每3周给药组各23例,化疗3个疗程及6个疗程后,评估不同方法的疗效、毒副作用,随访比较其复发时间及3年生存率。结果两组在骨髓抑制方面差异有统计学意义;其它毒性的概率,总体有效率,平均生存时间,中位生存时间,1、3、5年生存率差异无统计学意义。结论单周给药方案较3周给药方案骨髓抑制发生率低;但在总疗效、生存时间及生存率方面效果相当,具有低毒高效的优势。

Objective To explore the clinical safety,toxic and side effect,efficacy and recurrence time of the chemother-apy of paclitaxel plus carboplatin weekly and every three weeks in the treatment of ovarian cancer. Methods According to the protocol of China Gynecological Oncology Group （CGOG） treating the ovarian cancer in 2005, 46 patients in our hospital were equally randomly divided into two groups. One group received paclitaxel weekly while another group received paclitaxel every three weeks both with carboplatin. The efficacy,toxic and side effect, recurrence time of tumor and three-year survival rate were observed. Results There were no statistical differences in the other side effect, total response, the overall efficiency, mean survival time, median survival time and one,three,five-year survival rate between two groups except the incidence of Grade Ⅲ～Ⅳgranulocytopenia. Conclusion The scheme of paclitaxel plus carboplatin weekly is safer because of low myelosuppression rate while there are no statistical differences between the two schemes in the clinical efficacy , survival time and survival rate.